Login to Your Account

TopiVert Getting $12.5M for Topical Kinase Inhibitors

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 7, 2011
Two of the investors behind RespiVert Ltd., which was acquired by Johnson & Johnson subsidiary Janssen Biotech, Inc. (formerly Centocor Ortho Biotech Inc.) last year are hoping to repeat the success with a sequel. Imperial Innovations Group plc and SV Life Sciences are committing up to £8 million (US$12.5 million) to TopiVert Ltd., a new start-up focused on the discovery of topical kinase inhibitors for inflammatory conditions of the eye and gut.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription